Abstract
In the field of urological oncology, the progress of drug therapy has been remarkable in recent years, especially in the field of renal cell carcinoma, where research on cytokine therapy, such as IFNα therapy, has been actively conducted, and the development of immunotherapy has been promoted in a competitive manner. As of December 2021, several combination therapies such as PD-1 inhibitor plus anti-CTLA-4 antibody and PD-L1 inhibitor plus VEGFR-TKI are available as first-line treatment for advanced renal cell carcinoma in Japan.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
